Mithra Pharmaceuticals SA prides itself on representing strong values and a solid corporate philosophy. The company believes in innovation, collaboration, and excellence, which reflect in its products and services. With a focus on women's health, Mithra Pharmaceuticals aims to provide high-quality and accessible treatments that improve the lives of women worldwide. The company's commitment to research and development ensures cutting-edge solutions that address unmet medical needs. Mithra Pharmaceuticals SA consistently upholds its values of integrity, transparency, and social responsibility, forging ahead as a leader in the pharmaceutical industry.

Mithra Pharmaceuticals SA is primarily present in various countries and regions across the globe. With its headquarters in Belgium, the company focuses on strengthening its presence in Belgium, Europe, and international markets. Mithra has expanded its operations in countries like France, Germany, the Netherlands, Switzerland, Spain, Portugal, and the United Kingdom. Additionally, Mithra Pharmaceuticals has also established a presence in the United States, Asia, and emerging markets. Overall, Mithra Pharmaceuticals SA endeavors to serve patients and healthcare professionals worldwide through its global reach and strategic partnerships.

Mithra Pharmaceuticals SA has achieved several significant milestones over the years. One notable achievement is the successful development and commercialization of Estelle, a novel oral contraceptive, which has gained regulatory approvals in various countries. Additionally, Mithra has entered into numerous strategic partnerships and collaborations with renowned pharmaceutical companies, further expanding its global reach. The company's commitment to innovation is highlighted by the continuous development of innovative therapeutic solutions and technologies, leading to several patent approvals. Mithra Pharmaceuticals SA continues to strive towards advancing women's healthcare by delivering high-quality and breakthrough pharmaceutical products.

Mithra Pharmaceuticals SA is a renowned pharmaceutical company with a rich history and background. Founded in 1999, Mithra has been a pioneer in the development and commercialization of innovative women's health products. With a strong focus on research and development, Mithra has established itself as a global leader in contraception and hormone therapy. The company's commitment to improving women's health is demonstrated through its extensive product portfolio, which includes a range of contraceptive pills and hormone-based treatments. Mithra Pharmaceuticals SA continues to expand its market presence, aiming to provide women around the world with high-quality, effective pharmaceutical solutions.

The main competitors of Mithra Pharmaceuticals SA in the market include other pharmaceutical companies operating in the same therapeutic areas. These competitors may include larger pharmaceutical companies such as Johnson & Johnson, Novartis, Pfizer, and Merck, as well as smaller biotech firms specializing in similar products and treatments. Mithra Pharmaceuticals SA faces competition in the development, production, and commercialization of innovative pharmaceutical products and technologies. It strives to differentiate itself through a unique product portfolio, strong research and development capabilities, and strategic partnerships to remain competitive in the pharmaceutical industry.

Mithra Pharmaceuticals SA is primarily active in the pharmaceutical industry.

The business model of Mithra Pharmaceuticals SA is focused on developing, manufacturing, and commercializing innovative women's health products. As a biopharmaceutical company, Mithra specializes in the research and development of proprietary drugs, specifically in the fields of contraception, menopause, and hormone-dependent cancers. Mithra aims to provide safe, effective, and accessible solutions for women's healthcare needs worldwide. By leveraging their expertise in pharmaceutical science and strategic partnerships, Mithra Pharmaceuticals SA strives to improve the quality of life for women and contribute to positive health outcomes globally.

Det Mithra Pharmaceuticals P/E-forhold er -0,65.

Mithra Pharmaceuticals KUV er 0,23.

AlleAktien Kvalitetsscore for Mithra Pharmaceuticals er 3/10.

Den forventede Mithra Pharmaceuticals omsætning er 66,13 mio. EUR.

Den forventede Mithra Pharmaceuticals indtjening er -23,02 mio. EUR.

The company Mithra Pharmaceuticals SA is a Belgian company specializing in the development and marketing of innovative women's pharmaceuticals and products. The company was founded in 1999 and is based in Liege, Belgium. Mithra Pharmaceuticals' business areas include pharmaceuticals, medical devices, and contraceptives. In the pharmaceutical area, the company develops innovative drugs that improve women's health. This includes the development of hormone therapies for the treatment of menopausal symptoms (hormone replacement therapy). Another focus is the development of drugs for fertility treatment and the treatment of endometriosis. In the medical device area, the company offers products for pregnancy prevention. In addition to traditional contraceptive methods such as condoms and the pill, the company also develops innovative products such as hormone-free contraceptive rings and intrauterine contraceptive systems (IUS). Another focus of Mithra Pharmaceuticals is contraceptives. The company has developed a platform for the development of oral contraceptives based on the patented technology of estetrol synthesis. Estetrol is a naturally occurring sex hormone and offers a safe and effective alternative to currently available oral contraceptives. The company works closely with regulatory authorities and the medical community to ensure the efficacy, safety, and quality of its products. Additionally, Mithra Pharmaceuticals collaborates with leading companies in the pharmaceutical industry to market its products worldwide. With its innovative product pipeline and strong research and development department, Mithra Pharmaceuticals is able to meet the needs of women around the world. The company is committed to improving the lives of women by providing safe and reliable products and therapies. Overall, Mithra Pharmaceuticals' business model is focused on improving women's health worldwide by developing and marketing innovative products and therapies. The company aims to solidify its position as a leading provider of women's pharmaceuticals and products and achieve long-term, sustainable growth.

Mithra Pharmaceuticals udbetaler et udbytte på 0 EUR fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Mithra Pharmaceuticals, eller selskabet udbetaler ikke udbytte.

ISIN'en for Mithra Pharmaceuticals er BE0974283153.

WKN for Mithra Pharmaceuticals er A14V4E.

Tickeren for Mithra Pharmaceuticals er MITRA.BR.

I løbet af de sidste 12 måneder betalte Mithra Pharmaceuticals en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Mithra Pharmaceuticals sandsynligvis betale en dividende på 0 EUR.

Udbytteafkastet for Mithra Pharmaceuticals er i øjeblikket .

Mithra Pharmaceuticals betaler kvartalsvis udbytte. Dette uddeles i månederne .

Mithra Pharmaceuticals betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 EUR. Dette svarer til et dividendeafkast på 0 %.

Mithra Pharmaceuticals bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Mithra Pharmaceuticals fra den 5.7.2024 på 0 EUR, skulle du have haft aktien i din portefølje før ex-datoen den 5.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 5.7.2024.

I løbet af 2023 udbetalte Mithra Pharmaceuticals 0 EUR i form af dividender.

Udbytterne fra Mithra Pharmaceuticals udbetales i EUR.